Chemical and Pharmaceutical Bulletin
Online ISSN : 1347-5223
Print ISSN : 0009-2363
ISSN-L : 0009-2363
Current Topics: Regular Article
High-Affinity Anti-nivolumab DNA Aptamer: A Novel Capture Reagent for Its Bioanalysis by an Enzyme-Linked Aptamer Assay
Taisei Hojo, Nao Kobayashi, Chiho Hirayama, Jiaxing Tong, Naruma Uchidate, Aogu Furusho, Kenji Kojima, Eiji Sugiyama, Hajime Mizuno, Hideki Hayashi, Kenichiro Todoroki
Author information
JOURNAL OPEN ACCESS FULL-TEXT HTML
Supplementary material

2026 Volume 74 Issue 8 Pages 624-634

Details
Abstract

Bioanalysis of the immune checkpoint inhibitor nivolumab is crucial for pharmacokinetic studies. However, conventional ligand-binding assays (LBAs) often suffer from the lot-to-lot variability of capture antibodies. Here, we developed a high-affinity anti-nivolumab DNA aptamer as a robust alternative reagent. An integrated strategy combining Fast Protein Liquid Chromatography-based screening, next-generation sequencing, aptamer search algorithm, and computational modeling enabled rapid aptamer identification and optimization. The anti-nivolumab aptamer, mutant 2-3, discovered through in silico modification exhibited a dissociation constant (KD) of 33 nM. Using this aptamer, an enzyme-linked aptamer assay (ELAA) successfully quantified nivolumab in 400-fold diluted plasma samples over a range of 0.02–5.0 µg/mL, demonstrating good precision with a coefficient of variation less than 11.9%. This novel analytical method provides a sufficient quantitative range for the bioanalysis of nivolumab, thus offering a robust, specific, and cost-effective alternative for future pharmacokinetic studies.

Fullsize Image
Content from these authors
© 2026 The Author(s).
Published by The Pharmaceutical Society of Japan.

This article is licensed under a Creative Commons [Attribution-NonCommercial 4.0 International] license.
https://creativecommons.org/licenses/by-nc/4.0/
Previous article Next article
feedback
Top